Dr Moochhala is a consultant nephrologist and physician at the Royal Free Hospital. He has more than ten years' experience of consultant practice at the Royal Free London covering all aspects of kidney disease, including acute kidney injury, glomerulonephritis, hypertension, transplantation and all forms of dialysis.

Dr Moochhala is one of very few nephrologists in specialist centres who also maintains a general medical practice. This means that he is consulted by patients with a wide variety of medical and kidney problems. Dr Moochhala also sees patients with multi-system problems or where the specialty is unclear. He always tries to address all his patients’ medical issues and not just the kidney ones.

He is principal investigator at the Royal Free London for several international medical trials on rare kidney stone disease. He specialises in the diagnosis and management of rare stone-forming conditions, renal tubular and electrolyte disorders, hypertensive disorders and Fabry disease.

GMC number


  • Sadeghi-Alavijeh O, Chan M, Moochhala SH; Genomics England Research Consortium; Howles S, Gale DP, Böckenhauer D. Rare variants in the sodium-dependent phosphate transporter gene SLC34A3 explain missing heritability of urinary stone disease. Kidney Int. 2023 Jul 4:S0085-2538(23)00473-8. doi: 10.1016/j.kint.2023.06.019. PMID: 37414395. 
  • Moochhala SH, Worcester EM, Primary hyperoxaluria: the adult nephrologist's point of view, Clinical Kidney Journal, Volume 15, Issue Supplement_1, May 2022, Pages i29–i32, 
  • Hogh JN, Ebrahim H, Moochhala S, Ramaswami U. Early renal failure in childhood in a male with Fabry disease. BMJ Case Rep. 2022 May 10;15(5):e246682. doi: 10.1136/bcr-2021-246682. PMID: 35537774; PMCID: PMC9092140. 
  • Bargagli M, Moochhala S, Robertson WG, Gambaro G, Lombardi G, Unwin RJ, Ferraro PM. Urinary metabolic profile and stone composition in kidney stone formers with and without heart disease. J Nephrol. 2022 Apr;35(3):851-857. doi: 10.1007/s40620-021-01096-w. Epub 2021 Jun 21. PMID: 34152561; PMCID: PMC8995244. 
  • D’Ambrosio V, Moochhala S, Unwin RJ & Ferraro PM. Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis, Expert Review of Clinical Pharmacology 2022, 15:4, 407-414, DOI: 10.1080/17512433.2022.2082943 
  • Metry EL, Garrelfs SF, Peters-Sengers H, Hulton SA, Acquaviva C, Bacchetta J, Beck BB, Collard L, Deschênes G, Franssen C, Kemper MJ, Lipkin GW, Mandrile G, Mohebbi N, Moochhala SH, Oosterveld MJS, Prikhodina L, Hoppe B, Cochat P, Groothoff JW; OxalEurope Consortium. Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry. Kidney Int Rep. 2021 Nov 26;7(2):210-220. doi: 10.1016/j.ekir.2021.11.006. 
  • Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int. 2021 Sep;100(3):621-635. doi: 10.1016/j.kint.2021.03.031. 
  • Garrelfs S, Frishberg Y, Hulton S, Koren M, O’Riordan W, Cochoat P, Deschenes G, Shasha-Lavsky H, Saland J, van’t Hoff W, Fuster D, Magen D, Moochhala SH et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med 2021; 384:1216-1226. DOI: 10.1056/NEJMoa2021712 
  • Magni G, Unwin RJ, Moochhala SH. Renal tubular acidosis and kidney stones: diagnosis and management. Arch Esp Urol 2021; 74 (1): 123-128 
  • Ebrahim H, Lavalle L, Beaton B, Reed M, Moochhala S, Ramaswami U, Mehta A, Hughes D. Renal involvement in classical and late onset patients with Fabry disease and the role of co-existing pathologies. Molecular Genetics and Metabolism 2019; 126 (2): S51.
  • Ferraro, P.M., Arrabal-Polo, M.Á., Capasso, G. Moochhala S et al. A preliminary survey of practice patterns across several European kidney stone centers and a call for action in developing shared practice. Urolithiasis (2019) 47: 219.  

Dr Moochhala’s PhD research focused on the mechanisms of formation of calcium renal stones. Since then, he has published scientific papers, participated in interventional clinical trials, led teams collecting physiological and genetic information from patients with their consent and collaborated with leading kidney stone research groups internationally.

He is active at national level, having set up a national stone disease registry, sat as physician expert on a NICE guidelines committee, and organised national information days for patients and their families.

He is chair of two Rare Disease Groups, national chair of the NHS rare disease collaborative network for hyperoxaluria, and chair of OxalEurope.